When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

"The initial presentation typically includes dementia and neurological symptoms such as ataxia, myoclonus, and gait abnormalities as well as behavioral changes," Cetin and co-authors wrote. Sporadic ...

There are now more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...

Novo Nordisk is continuing its citizen petition crusade at the FDA, this time aiming to stop the compounding of Victoza, its ...

A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the ...

Fundsmith Equity, the largest investment fund in the UK, registered its fourth consecutive year of underperformance in 2024.